New GALDERMA R&D, Inc. International Research Facility 
10/19/2005 5:09:36 PM

FT. WORTH, Texas, Jan. 6 /PRNewswire/ -- Galderma R&D, the worldwide research and development arm of Galderma Laboratories, based in Sophia-Antipolis, France, has begun construction of a revolutionary new research center that will have major implications for Galderma, L.P., in the United States.

The new facility, named "Funel" sits in the hills of Sophia-Antipolis, between the Alps and the Mediterranean. The dramatically different architecture of this facility is designed to promote and encourage creativity, ensuring a surge in innovation and innovative thinking. The facility will be home for over 500 employees, 280 of whom will be scientists.

Galderma's considerable investment in people, technology and new research facilities has already in the past two years produced five new chemical entities, which are entering pre-clinical and/or early development phases within two strategic therapeutic areas -- acne and psoriasis. The development of these chemical entities will largely impact Galderma's R&D center in the U.S. International's goal is to develop compounds globally and submit the dossiers simultaneously in the U.S. and Europe.

The impact in the United States is expected to be considerable as the new facility dedicates itself to being the global leader in dermatology. "We are very excited about this new R&D entity," commented Galderma L.P. president, Humberto C. Antunes. "More and more dermatology is becoming an exceedingly critical medical specialty. As the population ages and various skin diseases manifest themselves in greater numbers of people, we see the need for medicine that has a very real effect. There is no doubt that damage and disease brought about by exposure to the sun is a very present danger for many segments of the population and we need drugs and technologies that can help people live longer and healthier lives." The new "Funel" facility creates proximity between researchers and work-centers encouraging the flow of information. Its open spaces and transparent walls, which separate the lab spaces, allow for permanent visibility, encouraging curiosity and practical exchanges between complementary work centers. The facility will combine skills in up-to-date technologies such as genomics, proteomics, early pharmacokinetics and high throughput technologies such as screening -- chemistry and toxico-genomics.

Galderma is a worldwide dermatology company with United States headquarters in Ft. Worth, TX. Galderma manufactures and markets both prescription and over-the-counter dermatology products such as Differin(R) (adapalene) Cream, Gel, 0.1%, MetroGel(R) (metronidazole topical gel) Topical Gel, 0.75%, Tri-Luma(R) Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%), Rosanil(TM) (sodium sulfacetamide 10% and sulfur 5%) Cleanser, Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution, and Cetaphil(R) Cleansers and Moisturizers.

Galderma R&D

CONTACT: Suzanne Lane of Lane & Coady P.R., +1-212-757-6880,